Dan Freeman

750 total citations
15 papers, 411 citations indexed

About

Dan Freeman is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Dan Freeman has authored 15 papers receiving a total of 411 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 6 papers in Pulmonary and Respiratory Medicine and 5 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Dan Freeman's work include HER2/EGFR in Cancer Research (5 papers), Monoclonal and Polyclonal Antibodies Research (5 papers) and Prostate Cancer Diagnosis and Treatment (3 papers). Dan Freeman is often cited by papers focused on HER2/EGFR in Cancer Research (5 papers), Monoclonal and Polyclonal Antibodies Research (5 papers) and Prostate Cancer Diagnosis and Treatment (3 papers). Dan Freeman collaborates with scholars based in United States, Australia and Germany. Dan Freeman's co-authors include Jennifer McNinch, Brian Varnum, Giorgio Senaldi, Charlie Starnes, Christine L. Shaklee, Thomas C. Boone, W. Scott Simonet, Gary Elliott, Jane Guo and Sheila Scully and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Journal of Clinical Oncology.

In The Last Decade

Dan Freeman

15 papers receiving 404 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Dan Freeman United States	8	182	165	110	44	42	15	411
J. Ishitoya Japan	8	180 1.0×	230 1.4×	83 0.8×	88 2.0×	42 1.0×	13	501
Luciana M. Laguinge United States	7	122 0.7×	309 1.9×	74 0.7×	19 0.4×	37 0.9×	9	471
Ken‐ichi Ohya Japan	15	160 0.9×	232 1.4×	253 2.3×	31 0.7×	51 1.2×	33	577
S. Fischer France	11	134 0.7×	224 1.4×	114 1.0×	25 0.6×	31 0.7×	19	424
Ondina Popescu Italy	13	139 0.8×	190 1.2×	83 0.8×	64 1.5×	86 2.0×	24	430
Pedro Cruz United States	13	194 1.1×	365 2.2×	65 0.6×	43 1.0×	87 2.1×	19	589
Maxime Pinard Canada	10	112 0.6×	306 1.9×	105 1.0×	33 0.8×	80 1.9×	20	499
Leslie A. Caromile United States	11	73 0.4×	163 1.0×	40 0.4×	85 1.9×	65 1.5×	16	358
Vasileios Mourmouras Italy	12	176 1.0×	214 1.3×	149 1.4×	31 0.7×	54 1.3×	17	530
Maryvonne Fourcin France	8	296 1.6×	125 0.8×	187 1.7×	15 0.3×	39 0.9×	9	413

Countries citing papers authored by Dan Freeman

Since Specialization

Citations

This map shows the geographic impact of Dan Freeman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dan Freeman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dan Freeman more than expected).

Fields of papers citing papers by Dan Freeman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dan Freeman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dan Freeman. The network helps show where Dan Freeman may publish in the future.

Co-authorship network of co-authors of Dan Freeman

This figure shows the co-authorship network connecting the top 25 collaborators of Dan Freeman. A scholar is included among the top collaborators of Dan Freeman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dan Freeman. Dan Freeman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

Freeman, Dan, Linda Lam, Bruce G. Raphael, et al.. (2021). Terraflow, a New High Parameter Data Analysis Tool, Reveals Systemic T-Cell Exhaustion and Dysfunctional Cytokine Production in Classical Hodgkin Lymphoma. Blood. 138(Supplement 1). 3516–3516. 1 indexed citations

Woods, David, Andressa S. Laino, Aidan Winters, et al.. (2020). Nivolumab and ipilimumab are associated with distinct immune landscape changes and response-associated immunophenotypes. JCI Insight. 5(11). 15 indexed citations

Freeman, Dan, Shaurya Gupta, D. Hudson Smith, et al.. (2019). Watson on the Farm: Using Cloud-Based Artificial Intelligence to Identify Early Indicators of Water Stress. Remote Sensing. 11(22). 2645–2645. 25 indexed citations

Abramowitz, Matthew C., Deukwoo Kwon, Dan Freeman, et al.. (2018). Early Toxicity and Patient Reported Outcomes from a Radiation Hypofractionation Randomized Trial of Extended vs Accelerated Therapy for Prostate Cancer (HEAT). International Journal of Radiation Oncology*Biology*Physics. 102(3). e98–e99. 1 indexed citations

Freeman, Dan & Christopher King. (2011). Stereotactic body radiotherapy for low-risk prostate cancer: Five-year outcomes.. Journal of Clinical Oncology. 29(7_suppl). 94–94. 1 indexed citations

Freeman, Dan, et al.. (2009). Stereotactic Body Radiotherapy: An Emerging Treatment Approach for Localized Prostate Cancer. International Journal of Radiation Oncology*Biology*Physics. 75(3). S307–S308. 7 indexed citations

Freeman, Dan, et al.. (2009). Abstract B171: U3-1287 (AMG 888), a fully human anti-HER3 mAb, demonstrates in vitro and in vivo efficacy in NSCLC models. Molecular Cancer Therapeutics. 8(12_Supplement). B171–B171. 5 indexed citations

Schneider, Matthias, Sabine Blum, Susanne Hartmann, et al.. (2009). Abstract B161: U3-1287 (AMG 888), a fully human anti-HER3 mAb, demonstrates preclinical efficacy in HER2+ and HER2− breast cancer models. Molecular Cancer Therapeutics. 8(12_Supplement). B161–B161. 3 indexed citations

Ruixo, Juan José Pérez, et al.. (2009). Abstract B167: Identifying first in human (FIH) doses and schedule of U3-1287 (AMG 888), a fully human anti-HER3 mAb, based on preclinical pharmacokinetic (PK), pharmacodynamic (PD) and efficacy data. Molecular Cancer Therapeutics. 8(12_Supplement). B167–B167. 4 indexed citations

10.

Treder, Martin, Susanne Hartmann, Eric Borges, et al.. (2008). Fully human Anti-HER3 monoclonal antibodies (mAbs) inhibit oncogenic signaling and tumor cell growth in vitro and in vivo. 68. 14 indexed citations

11.

Freeman, Dan, et al.. (2008). Panitumumab and cetuximab epitope mapping and in vitro activity. Journal of Clinical Oncology. 26(15_suppl). 14536–14536. 21 indexed citations

12.

Juan, Todd, et al.. (2007). Association of somatic kRAS gene mutations and clinical outcome from a phase 2 mCRC trial of panitumumab. Clinical Cancer Research. 13. 1 indexed citations

13.

Freeman, Dan, Ralf Lesche, Nathalie Kertesz, et al.. (2006). Genetic Background Controls Tumor Development in Pten -Deficient Mice. Cancer Research. 66(13). 6492–6496. 83 indexed citations

14.

Li, Gang, Yingchun Hu, Yanying Huo, et al.. (2006). PTEN Deletion Leads to Up-regulation of a Secreted Growth Factor Pleiotrophin. Journal of Biological Chemistry. 281(16). 10663–10668. 28 indexed citations

15.

Senaldi, Giorgio, Brian Varnum, Ulla M. Sarmiento, et al.. (1999). Novel neurotrophin-1/B cell-stimulating factor-3: A cytokine of the IL-6 family. Proceedings of the National Academy of Sciences. 96(20). 11458–11463. 202 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact